See more : Randgold & Exploration Company Limited (RNDXF) Income Statement Analysis – Financial Results
Complete financial analysis of Aadi Bioscience, Inc. (AADI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aadi Bioscience, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Salesforce, Inc. (FOO.F) Income Statement Analysis – Financial Results
- TS Corporation (001795.KS) Income Statement Analysis – Financial Results
- Super Bakers (India) Limited (SUPERBAK.BO) Income Statement Analysis – Financial Results
- Borosil Renewables Limited (BORORENEW.NS) Income Statement Analysis – Financial Results
- Royal Bafokeng Platinum Limited (RBP.JO) Income Statement Analysis – Financial Results
Aadi Bioscience, Inc. (AADI)
About Aadi Bioscience, Inc.
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.35M | 15.22M | 1.00M | 14.00M | 749.00K | 20.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.81M | 1.34M | 276.00K | 176.00K | 76.50K | 0.00 | 51.27K | 69.67K | 57.98K | 23.97K | 22.82K | 22.39K | 23.59K | 20.51K | 0.00 | 0.00 |
| Gross Profit | 21.55M | 13.88M | 724.00K | 13.82M | 672.50K | 20.16M | -51.27K | -69.67K | -57.98K | -23.97K | -22.82K | -22.39K | -23.59K | -20.51K | 0.00 | 0.00 |
| Gross Profit Ratio | 88.47% | 91.23% | 72.40% | 98.74% | 89.79% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 48.93M | 32.66M | 19.67M | 15.01M | 12.82M | 17.85M | 12.15M | 11.37M | 11.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 18.51M | 2.12M | 1.85M | 13.49M | 9.24M | 29.49K | 23.01K | 22.82K | 22.39K | 23.59K | 20.51K | 20.51K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 7.83M | -46.69K | -51.27K | 5.17M | 5.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 44.55M | 40.18M | 18.51M | 2.12M | 9.68M | 13.44M | 9.19M | 5.20M | 5.80M | 22.82K | 22.39K | 23.59K | 20.51K | 20.51K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 5.06M | -120.00K | -580.00K | -142.73K | -6.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -33.62K |
| Operating Expenses | 93.48M | 72.84M | 38.06M | 16.55M | 22.50M | 31.29M | 21.34M | 16.56M | 17.43M | 22.82K | 22.39K | 23.59K | 20.51K | 20.51K | 0.00 | -33.62K |
| Cost & Expenses | 96.29M | 74.17M | 38.06M | 16.55M | 22.58M | 31.34M | 21.39M | 16.63M | 17.49M | 22.82K | 22.39K | 23.59K | 20.51K | 41.02K | 0.00 | -33.62K |
| Interest Income | 6.40M | 2.40M | 13.00K | 41.00K | 1.03M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 231.00K | 230.00K | 665.00K | 815.00K | 0.00 | 778.22K | -105.78K | 9.94K | 8.43K | 5.88K | 4.97K | 3.60K | 1.89K | 1.89K | 0.00 | 0.00 |
| Depreciation & Amortization | 169.00K | 159.00K | 276.00K | 176.00K | 76.50K | 46.69K | 51.27K | 69.67K | 57.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -65.37M | -60.12M | -109.15M | -2.49M | -24.44M | -10.35M | -21.24M | -16.43M | -17.01M | -22.82K | -22.39K | -23.59K | -20.51K | -41.02K | 0.00 | -33.62K |
| EBITDA Ratio | -268.40% | -371.71% | -3,546.30% | -18.94% | -3,004.55% | -55.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -71.93M | -58.96M | -111.22M | -2.55M | -22.58M | -11.18M | -21.39M | -16.63M | -17.49M | -22.82K | -22.39K | -23.59K | -20.51K | -41.02K | 0.00 | -33.62K |
| Operating Income Ratio | -295.36% | -387.47% | -11,121.70% | -18.21% | -3,014.77% | -55.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.17M | 2.17M | 1.13M | -927.00K | 1.17M | 784.61K | -12.07K | -349.93K | 416.33K | 17.15K | 16.95K | 17.42K | 19.99K | 18.62K | 0.00 | 0.00 |
| Income Before Tax | -65.77M | -60.51M | -110.09M | -3.48M | -23.27M | -10.40M | -21.40M | -16.98M | -17.07M | -28.70K | -27.37K | -27.19K | -22.40K | -22.40K | 0.00 | -33.62K |
| Income Before Tax Ratio | -270.04% | -397.69% | -11,008.80% | -24.83% | -3,106.88% | -51.58% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.50M | 2.00K | 2.00K | 1.30K | 778.22K | -12.06K | -3.00 | 3.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -65.77M | -57.01M | -110.09M | -3.48M | -23.27M | -10.40M | -21.40M | -16.98M | -17.07M | -28.70K | -27.37K | -27.19K | -22.40K | -22.40K | 0.00 | -33.62K |
| Net Income Ratio | -270.04% | -374.67% | -11,009.00% | -24.84% | -3,106.88% | -51.58% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.44 | -2.53 | -12.34 | -20.52 | -8.60 | -4.60 | -14.81 | -9.42 | -9.47 | -0.02 | -0.02 | -0.02 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -2.44 | -2.53 | -12.34 | -20.52 | -8.60 | -4.60 | -14.81 | -9.42 | -9.47 | -0.02 | -0.02 | -0.02 | -0.01 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 26.92M | 22.51M | 8.92M | 169.49K | 2.71M | 2.26M | 1.44M | 1.80M | 1.80M | 1.80M | 1.80M | 1.80M | 1.80M | 5.00M | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 26.92M | 22.51M | 8.92M | 169.49K | 2.71M | 2.26M | 1.44M | 1.80M | 1.80M | 1.80M | 1.80M | 1.80M | 1.80M | 5.00M | 0.00 | 0.00 |
Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update
Company to Host Conference Call and Webcast on March 13, 2024 LOS ANGELES , March 6, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today...
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
LOS ANGELES , March 5, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR-driven cancers, today announced poster presentations at the 2024 American Association for Cancer Research (AACR),...
Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa
After 3 years of follow-up in AMPECT trial, confirmed clinically meaningful overall response rate, including multiple patients with complete responses Demonstrated 40 months median duration of response and median survival >53 months Historically, median survival has ranged from 16 to...
Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference
LOS ANGELES , Feb. 26, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, announced today its presentation at the TD Cowen 44th Annual Healthcare Conference,...
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium
Real-world genomic analysis highlights unmet medical need in GU cancer patients with TSC1/2 inactivating alterations LOS ANGELES , Jan. 26, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with...
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium
- New real-world analysis highlights unmet medical need in GI cancer patients with TSC1/2 alterations- LOS ANGELES , Jan. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with...
Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Why Is Aadi Bioscience (AADI) Stock Down 56% Today?
Aadi Bioscience (NASDAQ: AADI ) stock is falling on Friday following the release of interim clinical trial data from its PRECISION1 study. This clinical trial covers the use of nab-sirolimus as a treatment for patients with TSC1 or TSC2 inactivating alterations.
Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations
Interim results from investigator-assessed responses in first 40 patients from TSC1 and TSC2 arms demonstrate sustained tumor reductions in heavily pre-treated population 80 patients now enrolled in PRECISION1 supporting two-thirds interim analysis expected in 3Q 2024 Study on track for...
How Much Upside is Left in Aadi Bioscience, Inc. (AADI)? Wall Street Analysts Think 509.98%
The mean of analysts' price targets for Aadi Bioscience, Inc. (AADI) points to a 510% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an...
Source: https://incomestatements.info
Category: Stock Reports